




Anticoagulation Guideline for Hospitalized Adult and Pediatric COVID-19 Patients

ADULT BACKGROUND

- Severe COVID-19 disease is associated with features of disseminated intravascular coagulation (DIC) and hypercoagulable states which can manifest as venous thromboembolism (VTE) and/or microthrombosis.^{1,2}
- Centers for Disease Control and Prevention (CDC) estimates approximately 90% of hospitalized COVID-19 patients have underlying disease states such as obesity, hypertension, chronic lung disease, diabetes, and heart disease, which may increase risk of thrombosis.³
- Critically ill patients with COVID-19 have been reported to have a VTE incidence rate around 30% which is significantly higher than non-COVID-19 critically ill populations.^{4,5}
- Elevated D-dimer in the setting of severe COVID-19 pneumonia is associated with worse outcomes. Studies have found D-dimer above certain thresholds to have a high positive predictive value for VTE events and suggest these thresholds may be useful in determining when further diagnostic work up is warranted. However, the threshold associated with the highest risk is unknown.^{4,6-10}
- Randomized controlled trials (RCTs) have evaluated empiric therapeutic-dose anticoagulation in hospitalized COVID-19 patients. In critically ill patients, this strategy did not improve the primary outcome of days without organ support, and also increased major bleeding compared to prophylactic-dose anticoagulation.⁹
- In the non-critically ill population, empiric therapeutic-dose anticoagulation showed superiority over prophylactic-dose in increasing survival to hospital discharge and reduced need for organ support, with major bleeding occurring in 1.9% and 0.9% of patients in each group respectively.¹⁰ Reduced mortality, Intensive Care Unit (ICU) admissions, need for mechanical ventilation and a reduction in the composite endpoint of major thromboembolism or death were subsequently demonstrated in two additional RCTs^{11,12}, leading to adoption of this strategy in national guidelines.^{13,14}
- Hospitalized COVID-19 patients with a diagnosis necessitating therapeutic anticoagulation should be treated with treatment dose unfractionated or low molecular weight heparin (LMWH) instead of direct oral anticoagulants (DOACs) and warfarin which are less desirable due to illness-related hepatic dysfunction, reduced appetite and poor oral intake which may affect absorption or affect response to warfarin, and the possibility of rapid deterioration.^{15,16,17}
- Post-discharge thromboprophylaxis has not shown to improve outcomes in COVID-19 patients and should not routinely be prescribed. Carefully selected patients at continued high risk for VTE and low risk for bleeding may be considered, however validated risk assessment scoring tools in this specific setting are not available.^{17,18,19} Non-COVID-19 patient data suggests use of the modified IMPROVE VTE score coupled with the D-dimer to identify patients who may benefit from extended post-discharge thromboprophylaxis.²⁰
- The algorithms below are intended to provide guidance for anticoagulation prophylaxis and treatment in COVID-19 patients and should not supersede clinical judgement. They may also be applied to “Persons Under Investigation” (PUIs) at physician’s discretion.

Anticoagulation Algorithm for Adult Patients with COVID-19



**May consider checking LMW heparin assay 4 hrs after the 2nd dose to ensure target prophylaxis level (0.2-0.4) is achieved. High degree of inflammation may lead to a need for increased dosing.

***Patients presenting with trauma should continue to receive Enoxaparin 30 mg subcut BID per standard practice.

DOACs = Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban), Subcut = subcutaneously, TBW = Total body weight

Therapeutic Dose Prophylaxis Strategy

- Reserved for non-critically ill patients with moderate COVID-19 disease who DO NOT meet any of the following exclusion criteria.
- Exclusion Criteria: ^{9,10}
 - Current use of dual antiplatelet therapy
 - Platelet count < 50,000, INR > 2.0, or Hemoglobin < 8 g/dL
 - History of heparin induced thrombocytopenia
 - Acute or subacute bacterial endocarditis
 - Active bleeding
 - Risk factors for bleeding including: intracranial surgery, stroke or GI bleed within 3 months; history of intracerebral arteriovenous malformation or bleeding; intracranial malignancy; thrombolysis within previous 7 days, major surgery within previous 14 days, uncontrolled hypertension (SBP > 200 mmHg, DBP > 120 mmHg), presence of an epidural or spinal catheter

Post-Discharge Extended Thromboprophylaxis

- Not routinely recommended, but may be considered in carefully selected patients at continued high risk of VTE and low bleed risk for **14 - 30 days**
- Non-COVID-19 patient data¹⁷: modified IMPROVE VTE score ≥ 4 , or 2-3 plus elevated d-dimer; excluded patients with cancer, on dual antiplatelet therapy, active GI ulcer, bleeding in the previous 3 months, history of bronchiectasis/pulmonary cavitation
- Options include:
 - Rivaroxaban 10 mg PO once daily (avoid in severe hepatic or renal dysfunction) **OR** enoxaparin 40 mg subcut once daily
 - If CrCl < 30 mL/min: enoxaparin 30 mg subcut once daily **OR** heparin 5,000 units subcut every 8 hrs

PEDIATRIC BACKGROUND

- Most of what is known regarding thrombotic potential with COVID-19 infection is extrapolated from the adult literature. Despite duration of COVID-19 presence in the community, there is still little to be known about pediatric VTE risk and optimal prophylactic regimens. Prior to spread of delta variant, pediatric VTE prophylaxis consensus guidelines supported use of pharmacologic VTE prophylaxis in pediatric hospitalized patients with COVID-19 or multisystem inflammatory syndrome in children (MIS-C) diagnosis.¹
- Children infected with COVID-19 have previously demonstrated heterogeneity in clinical severity.² However, the delta variant strain proved to be more infectious³ and resulted in more children being hospitalized due to severity of symptoms (based on regional reports).
- A phase II study looking at safety, dosing, and efficacy of using twice daily VTE prophylaxis in COVID-19 positive patients ages 0-18 years has been completed without available publication at this time.⁴ Published expert opinion endorsed by the International Society of Thrombosis and Hemostasis (ISTH) recommend the following¹:
 - (Strong consensus; 83%) Suggest mechanical and pharmacologic VTE prophylaxis in hospitalized children with COVID-19 related illness or MIS-C who have:
 - Superimposed clinical risk factors (see table 1 below) **OR**
 - D-dimer ≥ 5 times the upper limit of normal

AND

 - No contraindication to anticoagulation (see table 2 below)

- (Weak consensus; 78%) Suggest low dose LMWH subcutaneously twice daily to achieve anti-Xa activity level of 0.2 to < 0.5 unit/mL in patients who are otherwise clinically stable without severe renal impairment in the absence of contraindications.
 - For patients with contraindications, consider continuous unfractionated heparin IV with anti-Xa activity target of 0.1 – 0.35 unit/mL
- (Strong consensus; 89%) Significant thrombocytopenia (count less than 20,000-50,000), hypofibrinogenemia (< 100 mg/dL by Clauss), ISTH defined major bleeding, concomitant aspirin administration at doses > 5 mg/kg/day likely confer higher risk of bleeding with anticoagulation. However, in the absence of other bleeding risk factors, low dose anticoagulation prophylaxis is not thought to increase risk of significant bleeding in MIS-C patients receiving aspirin doses ≤ 5 mg/kg/day for cardiac issues or Kawasaki-like disease.
- (Weak consensus; 61%) Continuation of anticoagulation prophylaxis post-discharge should be considered in pediatric patients with COVID-19 illness or MIS-C who have very elevated D-dimer at discharge **AND** superimposed risk factors (see table below). Duration of prophylaxis post-discharge should be until the clinical risk factor resolves OR 30 days post-discharge (whichever occurs sooner). Guidelines suggest using LMWH (i.e. enoxaparin) prophylaxis dosing twice daily or therapeutic dosing once daily (anti-Xa activity 0.5-1.0 unit/mL) in patients without contraindications or significant risk of bleeding.
- (Strong consensus; 89%) Suggest not routinely prescribing anticoagulation for VTE prophylaxis in hospitalized children with asymptomatic COVID-19 in the absence of central venous catheter OR multiple risk factors for hospital associated VTE (see table 1 below)


Table 1. Risk Factors for VTE in Pediatrics

Central venous catheter
Mechanical Ventilation
Prolonged length of stay: anticipated > 3 days
Complete immobility (Braden Q Mobility Score = 1)
Obesity (BMI > 95% for age percentile)
Active malignancy
Nephrotic syndrome
Cystic fibrosis exacerbation
Sickle cell disease vaso-occlusive crisis
General inflammatory disease flare (i.e., Lupus, JIA, Inflammatory bowel disease)
Congenital or acquired cardiac disease with venous stasis or impaired venous return
Prior history of VTE
First degree family history of VTE prior to 40 yr of age OR unprovoked VTE
Known thrombophilia (i.e., Protein S or protein C deficiency, ATIII deficiency, Factor V Leiden, Prothrombin II mutation, anti-phospholipid antibodies)
Pubertal, post-pubertal, or > 12 years of age
Receiving estrogen containing oral contraceptive pill
Status-post splenectomy for underlying hemoglobinopathy

Table 2. Contraindications for Anticoagulation in Pediatrics

Absolute:
Hemorrhage, evidence or high risk of
Relative:
Bleeding disorder, known tendency – consult Pedi Hematology
Platelet count unable to be sustained > 50,000mm ³ (contraindication depends on etiology)
Intracranial mass
Lumbar puncture or epidural catheter removal in prior 12 hours
Neurosurgical procedure
Pelvic fracture within past 48 hours
Uncontrolled hypertension

Anticoagulation Algorithm for Pediatric Patients with COVID-19



^Recommend screening for personal and family history of bleeding disorder in addition to screening coagulation labs prior to anticoagulation.

*Recommend prophylaxis if no contraindications exist (Table 2). LMWH thromboprophylaxis guidelines located [at this link](#). Recommend q12hr dosing with goal anti-Xa activity of 0.2 to < 0.5 unit/mL. Unfractionated heparin guidelines located [at this link](#). Consider heparin infusion if there are contraindications to LMWH or severe renal impairment. Recommend continuous IV infusion with target anti-Xa activity 0.1 - 0.35unit/mL.

≠Consider trending D-dimer daily

#Post-discharge VTE prophylaxis should be considered in patients who have markedly elevated D-dimer at discharge and superimposed risk factors (Table 1). Duration of prophylaxis post-discharge should be until the clinical risk factor resolves OR 30 days post-discharge (whichever occurs sooner). Suggest using LMWH prophylaxis dosing twice daily (anti-Xa activity 0.2 to < 0.5unit/mL) in patients without contraindications (Table 2) or significant risk of bleeding. Refer patients who are discharged on LMWH to follow-up in Hematology Clinic with Dr. Maida or the nurse practitioner within 1 week.

ADULT REFERENCES

1. Yuriditsky E, Horowitz JM, Merchan C, et al. Thromboelastography profiles of critically ill patients with coronavirus disease 2019. *Crit Care Med*. 2020; [published online ahead of print]. <https://doi.org/10.1097/ccm.0000000000004471>
2. Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia. *Emerg Microbes & Infect*. 2020;9(1):727-732.
3. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:458–464. DOI: <http://dx.doi.org/10.15585/mmwr.mm6915e3>
4. Trigonis RA, Holt DB, Yuan RY, et al. Incidence of thromboembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation. *Crit Care Med*. 2020; [published online ahead of print]. doi: 10.1097/CCM.0000000000004472
5. Klok FA, Kruip MJ, Van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020 (191);145-147.
6. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720.
7. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18:844-847.
8. Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. *J Thromb Thrombolysis*. 2020; [published online ahead of print] doi.org/10.1007/s11239-020-02105-8
9. The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. *N Engl J Med*. DOI:10.1056/NEJMoa2103417.
10. The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *N Engl J Med*. DOI:10.1056/NEJMoa2105911.
11. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. *BMJ*. 2021;375:n2400.
12. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. *JAMA Intern Med*. 2021.
13. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [August 18, 2022].
14. Barnes, G.D., Burnett, A., Allen, A. et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. *J Thromb Thrombolysis* **54**, 197–210 (2022). <https://doi.org/10.1007/s11239-022-02643-3>
15. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: Interim clinical guidance from the Anticoagulation Forum. *J Thromb Thrombolysis*. 2020;50(1):72-81.
16. Moores LK, Tritschler T, Brosnahan S, Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. *Chest*. 2020; [published online ahead of print]
17. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost* 2020; 18:1859.
18. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [August 13, 2021].
19. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. *Blood Adv* 2021;5(3):872-888. <https://doi.org/10.1182/bloodadvances.2020003763>
20. Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. *TH Open Companion J Thromb Haemost* 2020;4:e59–65. <https://doi.org/10.1055/s-0040-1705137>.

PEDIATRIC REFERENCES

1. Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. *J Thromb Haemost*. 2020;18:3099-3105.
2. Cruz AT, Zeichner SL. COVID-19 in children: initial characterization of the pediatric disease. *Pediatrics*. 2020;145(6):e20200834.
3. CDC. Delta Variant: What We Know About the Science. Aug 6, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html>
4. <https://clinicaltrials.gov/ct2/show/NCT04354155>. Accessed Aug 18, 2021.

Approved by Anticoagulation Safety Committee: 4/16/2020; 7/27/2020; 09/15/2021, 10/21/2022

Approved by Pediatric P & T Subcommittee: 9/7/21

Approved by Pharmacy & Therapeutics Committee: 4/17/2020; 8/4/2020; 10/01/2021 (Expedited); 01/05/2023 (Expedited)